Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Net Margin (2016 - 2024)

Arcadia Biosciences filings provide 11 years of Net Margin readings, the most recent being 2.22% for Q4 2024.

  • On a quarterly basis, Net Margin rose 93021.0% to 2.22% in Q4 2024 year-over-year; TTM through Sep 2025 was 0.52%, a 21524.0% increase, with the full-year FY2024 number at 53.93%, up 12200.0% from a year prior.
  • Net Margin hit 2.22% in Q4 2024 for Arcadia Biosciences, up from 27.98% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 817.15% in Q1 2020 to a low of 3448.04% in Q2 2020.
  • Median Net Margin over the past 5 years was 32.75% (2024), compared with a mean of 288.3%.
  • The widest YoY moves for Net Margin: up 879943bps in 2020, down -553523bps in 2020.
  • Arcadia Biosciences' Net Margin stood at 246.21% in 2020, then tumbled by -47bps to 130.05% in 2021, then plummeted by -85bps to 19.75% in 2022, then tumbled by -4821bps to 932.43% in 2023, then soared by 100bps to 2.22% in 2024.
  • The last three reported values for Net Margin were 2.22% (Q4 2024), 27.98% (Q3 2024), and 60.41% (Q2 2024) per Business Quant data.